PRODUCT NAME | QUALITY GRADE | STATUS |
Ranolazine | In-House/ USP PF 44(3) | US DMF Filed EU ASMF Filed China NMPA DMF Filed |
Pregabalin | IP/ USP/ Ph. Eur/ BP/ In-House | US DMF Filed China NMPA DMF Filed CEP Granted JDMF Filed KDMF Filed ANVISA DMF Filed |
Sugammadex Sodium | In-House | EU ASMF Filed |
Dolutegravir Sodium | In-House | WHO DMF Under Compilation |
Levocetirizine DI-HCL | USP/IP/In-House | Validation Completed |
Empagliflozin | In-House | In-House DMF Available |
Ziprasidone DI-HCL | USP/IP | In-House DMF Available |
Doxazosin Mesylate | USP/BP/In-House | In-House DMF Available |
Alfuzosin HCL | USP/Ph.Eur | In-House DMF Available |
Cetirizine DI-HCL | USP/Ph.Eur/IP/BP | In-House DMF Available |
Prazosin HCL | USP/EP | In-House DMF Available |
Silodosin | In-House | In-House DMF Available |
Darunavir Ethanolate | In-House | Under Validation |
Ziprasidone Mesylate Trihydrate | Ph.Eur/In-House | Under Validation |
Sitagliptin Phosphate Monohydrate | USP/ Ph.Eur/ IP | Under Validation |
Oclacitinib Maleate [VET] | In-House | Tech Pack Ready |
Azilsartan Base | In-House | Tech Pack Ready |
Sitagliptin HCL | In-House | Tech Pack Ready |
Avibactam Sodium | In-House | Under Development |
Azilsartan Medoxomil | In-House | Under Development |
Bempedoic Acid | In-House | Under Development |
Bilastine | In-House | Under Development |
Candesartan Cilexetil | In-House | Under Development |
Dabigatran Etexilate Mesylate | In-House | Under Development |
Fosravuconazole | In-House | Under Development |
Garenoxacin | In-House | Under Development |
Pentosan Polysulfate Sodium | In-House | Under Development |
Terazosin HCL | USP | Under Development |